SCHEMBL4285392

SCHEMBL4285392

O=c1nc(NO)ccn1[C@@H]1C=C[C@H](CO)O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.43
ALB P02768 3/20 0.43
POLB P06746 2/20 0.43
ALDH1A1 P00352 2/20 0.43
BLM P54132 2/20 0.43
ADRA1A P35348 1/20 0.43
ABL1 P00519 1/20 0.39
RIN1 Q13671 1/20 0.39
MTOR P42345 2/20 0.39
THRB P10828 1/20 0.39
MDM2 Q00987 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
PDE3A Q14432 3/20 0.35
CACNA1F O60840 2/20 0.35
MAPT P10636 2/20 0.35
CACNA1D Q01668 2/20 0.35
CACNA1S Q13698 2/20 0.35
CACNA1C Q13936 2/20 0.35
DUT P33316 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10509560 0.85 ABL1 (0.43) LMNAALBPOLBALDH1A1BLM
SCHEMBL4280947 0.82 DUT (0.40) POLBABL1RIN1DUTP2RY6
SCHEMBL10512146 0.82 ABL1 (0.41) LMNAALBPOLBALDH1A1BLM
SCHEMBL3782352 0.81 ABL1 (0.63) LMNAALBPOLBALDH1A1BLM
SCHEMBL7154210 0.81 LMNA (0.55) LMNAALBPOLBALDH1A1BLM
SCHEMBL5821 0.81 LMNA (0.55) LMNAALBPOLBALDH1A1BLM
SCHEMBL1980249 0.81 LMNA (0.55) LMNAALBPOLBALDH1A1BLM
SCHEMBL14580321 0.81 LMNA (0.55) LMNAALBPOLBALDH1A1BLM
SCHEMBL10509638 0.80 ABL1 (0.46) POLBALDH1A1ABL1RIN1CACNA1C
SCHEMBL10338478 0.78 DEGS1 (0.40) LMNAALBPOLBALDH1A1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105186-A1 Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105186-A1 Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases TYMP, ENTPD5, NUDT1 LMNA 256/4885ALB 3936/4885POLB 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.